policy
| 4 min read
A massive cancer drug deal, a new license for gut-targeted drugs, and both regulatory and company-led halts on clinical trials led the news this week.
| 4 min read
Vaccination guidances, promising trial outcomes, funding bills and more led the news this week.
| 5 min read
What commercialization looks like when headcount shrinks, launches can’t miss, and geography becomes a risk decision.
| 3 min read
Tariff-free US access and pricing reforms give the UK a potential edge in an uncertain global market.
| 5 min read
The life sciences sector contributes billions to the economy, but current policy and international factors are threatening growth.
| 4 min read
In vivo CAR T, lab-grown eggs, trial access, postpartum depression, and RNA therapy for hereditary angioedema led drug discovery this week.
| 4 min read
Sepsis antibody breakthroughs, a billion-dollar KRAS deal, and FDA’s push to rebuild domestic drug manufacturing led the drug discovery news this week.
| 4 min read
Big-ticket licensing, FDA shake-ups, and Alzheimer’s data led the news this week.
| 4 min read
A new CRISPR center for kids, Trump threatens 200 percent tariffs on foreign-made drugs, the first malaria treatment for babies, and more led this week’s news.
| 4 min read
The Bethesda Declaration, a new RSV antibody for kids, amylin’s promising weight loss results, and more were industry’s need-to-know stories this week.
